Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
14.9 USD -2.36% Intraday chart for CVRx, Inc. -13.52% -52.61%
Sales 2024 * 54.89M Sales 2025 * 76.74M Capitalization 330M
Net income 2024 * -41M Net income 2025 * -34M EV / Sales 2024 * 5.33 x
Net cash position 2024 * 37.11M Net cash position 2025 * 12.66M EV / Sales 2025 * 4.13 x
P/E ratio 2024 *
-7.8 x
P/E ratio 2025 *
-9.81 x
Employees 200
Yield 2024 *
-
Yield 2025 *
-
Free-Float 83.61%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.36%
1 week-13.52%
Current month-18.18%
1 month-27.91%
3 months-43.84%
6 months+16.04%
Current year-52.61%
More quotes
1 week
14.68
Extreme 14.68
17.41
1 month
14.68
Extreme 14.68
21.67
Current year
14.68
Extreme 14.68
32.43
1 year
9.18
Extreme 9.18
33.14
3 years
4.60
Extreme 4.6
33.14
5 years
4.60
Extreme 4.6
33.14
10 years
4.60
Extreme 4.6
33.14
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 22-12-20
Director of Finance/CFO 41 15-07-31
Chief Operating Officer - 06-06-30
Members of the board TitleAgeSince
Director/Board Member 59 08-09-30
Director/Board Member 50 20-06-30
Director/Board Member 55 20-06-30
More insiders
Date Price Change Volume
24-04-19 14.9 -2.36% 109,422
24-04-18 15.26 -2.86% 89,693
24-04-17 15.71 -4.09% 93,961
24-04-16 16.38 -1.50% 69,594
24-04-15 16.63 -3.48% 101,388

Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT

More quotes
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.26 USD
Average target price
34 USD
Spread / Average Target
+122.80%
Consensus